Factor | Number of patients included in the relevant step | p-value of the likelihood ratio test | hazard ratio | 95% confidence interval of hazard ratio |
---|---|---|---|---|
Event free survival | ||||
LDH at diagnosis (abnormal vs. normal) | 325 | .020 | 2.155 | 1.129 - 4.113 |
MYCN (amplified vs. normal) | 264 | .009 | 1.565 | 1.117 - 2.191 |
Age at diagnosis (continuous) | 334 | <.001 | 1.099 | 1.054 - 1.146 |
ASCT (yes vs. no) | 334 | .016 | .647 | .453 - .923 |
Consolidation treatment | 334 | .068 | ||
NB90 maintenance vs. MAB ch14.18 | .688 | 1.083 | .733 - 1.601 | |
No consolidation vs. MAB ch14.18 | .021 | 1.625 | 1.077 - 2.453 | |
Protocol (NB90 vs. NB97) | 334 | .106 | ||
Overall survival | ||||
LDH at diagnosis (abnormal vs. normal) | 325 | .016 | 2.315 | 1.170 - 4.578 |
MYCN (amplified vs. normal) | 264 | <.001 | 1.182 | 1.085 - 1.289 |
Age at diagnosis (continuous) | 334 | <.001 | 1.111 | 1.062 - 1.161 |
ASCT (yes vs. no) | 334 | .036 | .673 | .464 - .975 |
Consolidation treatment | 334 | .031 | ||
NB90 maintenance vs. MAB ch14.18 | .182 | 1.317 | .879 - 1.975 | |
No consolidation vs. MAB ch14.18 | .011 | 1.737 | 1.134 - 2.661 | |
Protocol (NB90 vs. NB97) | 334 | .162 |